Introduction
============

Depression commonly co-occurs with Parkinson's disease (PD) with prevalence rates of 20%--50% based on community samples ([@b12-ndt-2-375]; [@b37-ndt-2-375], [@b36-ndt-2-375]). The high comorbidity between depression and PD has been attributed to both neurodegenerative changes in the mesocorticolimbic pathway in the frontal striatal regions of the brain ([@b34-ndt-2-375]) and the affective distress related to functional impairment ([@b9-ndt-2-375]). Depression in PD patients is a significant health concern that has been linked to increased disability and decreased quality of life ([@b15-ndt-2-375]; [@b40-ndt-2-375]; [@b21-ndt-2-375]; [@b20-ndt-2-375]; [@b25-ndt-2-375]; [@b35-ndt-2-375]) as well as increased mortality ([@b18-ndt-2-375]) and risk of suicide ([@b30-ndt-2-375]). In addition, patient depression has also been shown to negatively affect PD caregivers and is commonly linked to caregiver depression and distress ([@b1-ndt-2-375]; [@b27-ndt-2-375]; [@b13-ndt-2-375]).

Mild cognitive impairment (MCI), a syndrome referring to cognitive impairments that do not meet criteria for dementia ([@b11-ndt-2-375]; [@b43-ndt-2-375]), is also common in PD, with estimates of MCI in PD clinical samples ranging from 10% to 55% ([@b32-ndt-2-375]; [@b19-ndt-2-375]; [@b7-ndt-2-375]; [@b17-ndt-2-375]; [@b45-ndt-2-375]). Among depressed PD patients the incidence of MCI is likely higher as depression can exacerbate cognitive symptoms ([@b42-ndt-2-375]). The current standard of practice for treating depression among individuals with PD is psychopharmacological intervention ([@b39-ndt-2-375]; [@b24-ndt-2-375]; [@b38-ndt-2-375]; [@b22-ndt-2-375]). However, concerns regarding the efficacy and safety of these medications have been raised ([@b38-ndt-2-375]) and a significant portion of PD patients being treated for depression often do not respond to one or more trials of pharmacotherapy ([@b44-ndt-2-375]). Although there have not yet been studies investigating the effectiveness of pharmacological interventions specifically for older PD patients with MCI, these individuals may be further at risk for poor and unstable response to antidepressants due to changes in the frontal-subcortical brain regions ([@b2-ndt-2-375]).

Given the prevalence of depression among PD patients, the impact of depression on patient quality of life, and the potential for poor responses to pharmacotherapy, there is a surprising lack of research on evidence-based psychotherapeutic interventions for these individuals. This is particularly apparent given the usefulness of psychotherapeutic interventions in late life depression ([@b5-ndt-2-375]). Problem solving therapy (PST), in particular, has been shown to be effective for the treatment of depression in older adults ([@b6-ndt-2-375]), older adults with mild cognitive impairment ([@b3-ndt-2-375]), and depressed medically frail elders ([@b29-ndt-2-375]). This case study is presented to raise awareness of the need to develop evidence-based psychotherapeutic interventions for depression among individuals with PD and MCI.

The case: PK
============

Presenting complaint
--------------------

The patient is an 83-year-old Caucasian woman with PD who was diagnosed with major depressive disorder (MDD) based on a structured clinical interview for the Diagnostic and Statistical Manual of Mental Disorders-IV ([@b4-ndt-2-375]). The onset of depressive symptoms began approximately 5 years ago with gradual worsening over this interval. Suicidal ideation was denied and the patient had no prior history of treatment for depression. The patient is non-ambulatory and has resided in a long-term skilled nursing home since 2003. The patient endorsed mild memory difficulties; other cognitive difficulties were denied.

Medical history
---------------

The patient's medical history was significant for PD and hypertension. Recent head imaging (CT) indicated a generalized prominence of the ventricles and sulci consistent with generalized atrophy. Additionally, areas of low attenuation were reported in periventricular and subcortical areas without evidence of cortical infarction, hemorrhage or mass lesion. Her medications included: docusate (250 mg), prilosec (20 mg), hydralazine (50 mg), divalproex sodium 500 mg, carbidopa--levodopa (25 mg/100 mg), gabapentin (300 mg), furosemide (40 mg).

Cognitive assessment
--------------------

The patient participated in a neuropsychological screening assessment prior to treatment as part of her intake evaluation. The cognitive evaluation consisted of the following measures: the Mini-Mental State Exam ([@b14-ndt-2-375]), the Wisconsin Card Sorting Test-64 Computer Version 2 (WCST) ([@b33-ndt-2-375]), the Stroop Color and Word Test ([@b41-ndt-2-375]), the Hopkins Verbal Learning Test - Revised (HVLT-R) ([@b8-ndt-2-375]), and the Dementia Rating Scale-2 (DRS-2) ([@b26-ndt-2-375]). The results of this screening evaluation ([Table 1](#t1-ndt-2-375){ref-type="table"}) indicate that the patient demonstrated relative strengths in attention, constructional ability, and conceptualization ability. Mild impairments were observed on measures of executive function and memory. These observed cognitive deficits, in conjunction with a review of functional status, were consistent with a diagnosis of mild cognitive impairment. They did not warrant a DSM-IV diagnosis of dementia since these cognitive deficits were mild and did not significantly impair social functioning. Nonetheless, these impairments had the potential of limiting the effectiveness of psychotherapy, as psychotherapy involves learning new skill sets, remembering information from previous sessions, problem solving, and planning abilities.

Measures of depression severity
-------------------------------

The Hamilton Depression Rating Scale ([@b16-ndt-2-375]) is a 17-item instrument yielding scores from 0 to 34; high scores indicate greater severity of depression. The HDRS is an interviewer-rated instrument shown to be sensitive to change over time and has been shown to be a be a valid measure of depressive symptoms with Parkinson's patients ([@b23-ndt-2-375]; [@b10-ndt-2-375]).

The Montgomery Asberg Depression Rating Scale (MADRS) ([@b28-ndt-2-375]) is a commonly used measure of severity of depressive symptoms ([@b46-ndt-2-375]) which has been validated with Parkinson's patients ([@b23-ndt-2-375]; [@b10-ndt-2-375]).

Intervention
------------

The psychotherapeutic intervention consisted of 12 one-hour sessions with a licensed therapist following a structured PST protocol. The patient did not utilize antidepressant medications during the course of this treatment or the subsequent follow-up period. PST for older adults with executive dysfunction was developed by Areán ([@b3-ndt-2-375]) to specifically accommodate cognitive problems commonly experienced among older depressed adults. The premise of the intervention is that depression is caused, in part, by difficulty coping with psychosocial problems ([@b31-ndt-2-375]). The therapy is designed to help individuals overcome depression by teaching them a systematic way of solving these problems while accommodating mild cognitive impairments. The major components of the therapy include 8 stages: 1) Selecting and defining problems, 2) Establishing realistic goals, 3) Generating alternative solutions to meet stated goals, 4) Implementing decision making guidelines, 5) Evaluating and choosing solutions, 6) Implementing the preferred solution, 7) Evaluating the outcome, and 8) Activity scheduling.

During the first session of PST with PK, the therapist explained the rationale for PST and emphasized the relationship between depression and problem solving skills. During this session, the therapist and patient created an extensive list of psychosocial problems the patient was experiencing. PK's initial problem list consisted of problems such as "I feel lonely," "I'm bored," "I'm too dependent on others". The therapist then helped the patient to select and define her most significant problem ("worrying about my health"). For the remainder of the session this problem was focused on as a way of introducing the remaining 7 stages--steps of PST. After defining her chosen problem and establishing realistic goals, the patient was encouraged to generate alternative solutions and implement decision-making guidelines to choose her best solution. In the subsequent session, PK was able to report that she was able to implement and evaluate the outcome of her preferred solution.

As therapy progressed PK became more familiar with the steps of PST and reported that she felt progressively "more in control" of her health. By session \#7, she reported that she was able to apply her problem solving approach independently in many situations, such as finding a safe and effective method of transferring herself from her wheelchair to the toilet in order to void independently, as well as identifying the need for, and steps to obtain, an amplified phone. She utilized these successes to develop increased activity planning, such as participating more consistently in daily activities offered at her residential facility including yoga and art classes, and reconnecting with friends by phone.

PK completed 12 sessions of PST and at the conclusion of her treatment she no longer met criteria for major depressive disorder based on DSM-IV criteria (assessed by a licensed therapist with a structured clinical interview). Assessments of depression severity at 1-month and 6-months post treatment indicated treatment gains were maintained. Depression severity scores for the intervention and follow-up period are shown in [Figure 1](#f1-ndt-2-375){ref-type="fig"}. Qualitatively, PK attributed improvements in mood status to learning that even "big problems can be broken down into more workable pieces".

Discussion
==========

Given the prevalence of MDD and MCI in individuals with PD, there is a surprising lack of evidence-based research on psychotherapeutic interventions for these individuals. This is particularly relevant due to concerns regarding the efficacy and safety of pharmacological interventions for MDD among individuals with PD, and the efficacy of PST in the treatment of depression in older adults who are medically frail and/or have mild cognitive impairments. We presented this case study to raise awareness that PST may be an effective treatment for MDD with PD and concurrent MCI. Additionally, although formal measures of disability were not administered, PK reported that PST had the added benefit of minimizing disability; a finding not traditionally associated with pharmacological interventions alone.

Conclusions
===========

This case study suggests that PST holds promise for treating depression among PD patients with MCI and may also be helpful in decreasing disability for these individuals. Randomized clinical trials should be conducted to evaluate the effectiveness of structured psychotherapeutic interventions for the treatment of MDD among patients with PD and MCI to determine the generalizability of these findings.
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###### 

Results of cognitive screening evaluation

  Measure                                 %ile
  --------------------------------------- ------------------------------------------------
  Mini Mental State Exam                  25/30[a](#tfn1-ndt-2-375){ref-type="table-fn"}
  Dementia Rating Scale -2                
   Attention                              19--28
   Initiation/perseveration               6--10
   Construction                           41--59
   Conceptualization                      19--28
   Memory                                 6--10
   DRS total score                        6--10
  Stroop Test Color-Word Score            3
  Wisconsin Card Sorting Test (64 Card)   
   Categories completed                   6--10
   Total errors                           4
   Perseverative errors                   1
  Hopkins Verbal Learning Test            
   Acquisition                            1
   Long delay free recall                 7
   Long delay cued recall                 25

raw score.
